title: Sublingual desensitization in children with congenital malformations and latex allergy.
abstract: The frequency of latex allergy in children requiring multiple surgery ranges from 16.7% to 65%. The aim of this study was to investigate the safety and efficacy of latex desensitization in a group of 10 patients with a history of multiple surgical procedures and clinically manifested allergy to latex. We selected 10 children (female-male ratio = 5:5), aged 4-16 yr (mean +/- s.d.: 9 +/- 4), with a history of multiple surgical procedures, adverse reactions to latex and positive skin test to latex and/or specific immunoglobulin E (IgE). Latex allergy diagnosis was confirmed by specific provocation tests (cutaneous, sublingual, mucous, conjunctival tests). Rush (4-day) sublingual desensitization was performed with increasing doses of latex extract (ALK Abellò) under patients' tongue until the highest dose of 500 microg of latex. A maintenance therapy (10 drops of undiluted solution three times a week) was recommended. During the 2-yr follow-up mean values of specific IgG4 and IgE, eosinophilic cationic protein and total IgE did not show significant variations. Patients did not manifest any adverse effect during the rush phase and only two patients manifested mild local symptoms during the maintenance therapy. All the challenges showed a reduction in terms of percentage of positivity and mean scores. All the patients showed a reduction of the mean individual score (p < 0.001). Furthermore patients who needed dental examination or surgery underwent such procedures without the occurrence of symptoms. Our preliminary results show sublingual desensitization to latex can be an important therapeutic tool in the management of young allergic patients requiring multiple operations.
authors.affiliation: Department of Allergology, Università Catholica Del Sacro Cuore, Policlinico, A. Germelli, Rome, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Nucera
authors.forename: D
authors.initials: D
authors.lastname: Schiavino
authors.forename: E
authors.initials: E
authors.lastname: Pollastrini
authors.forename: C
authors.initials: C
authors.lastname: Rendeli
authors.forename: D
authors.initials: D
authors.lastname: Pietrini
authors.forename: F
authors.initials: F
authors.lastname: Tabacco
authors.forename: T
authors.initials: T
authors.lastname: De Pasquale
authors.forename: E
authors.initials: E
authors.lastname: Ausili
authors.forename: V
authors.initials: V
authors.lastname: Sabato
authors.forename: C
authors.initials: C
authors.lastname: Roncallo
authors.forename: G
authors.initials: G
authors.lastname: Patriarca
mesh_terms: D000286:Administration, Sublingual; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D000013:Congenital Abnormalities / Q000601:surgery; D047150:Eosinophil Cationic Protein / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007840:Latex / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D020315:Latex Hypersensitivity / Q000628:therapy*; D008297:Male; D019990:Perioperative Care; D013514:Surgical Procedures, Operative
chemical_list: D007074:Immunoglobulin G; D007840:Latex; D007073:Immunoglobulin E; D047150:Eosinophil Cationic Protein